Two Doses of Recombinant Zoster Vaccine Highly Effective
Two doses of recombinant zoster vaccine (RZV) are effective against herpes zoster, with 76% efficacy, supporting the recommendation for a second dose.
Read MoreMar 2, 2024
Two doses of recombinant zoster vaccine (RZV) are effective against herpes zoster, with 76% efficacy, supporting the recommendation for a second dose.
Read MoreMar 2, 2024
Tailored efforts addressing age, socioeconomic status, and social support can boost PrEP use among Latino MSM, reducing HIV disparities.
Read MoreMar 2, 2024
Low PrEP initiation (21.8%) and high discontinuation (37.5/100 person years) observed among transgender women, with reasons unrelated to HIV risk.
Read MoreFeb 29, 2024
1. In this cohort study, patients with uncomplicated gram-negative bacteremia who were switched...
Read MoreFeb 27, 2024
1. Elderly participants who consumed cannabis 30 minutes before driving in a simulator were found...
Read MoreFeb 26, 2024
Women in health care occupations endure a significantly higher level of stress and burnout than...
Read MoreFeb 23, 2024
1. Having a greater number of unmet social needs was associated with lower utilization of...
Read MoreFeb 12, 2024
GoFundMe started as a crowdfunding site for underwriting “ideas and dreams,” and, as GoFundMe’s...
Read MoreJan 18, 2024
Various factors impact the risk for subsequent respiratory conditions among children with RSV before age 2, including prematurity and socioeconomic status.
Read MoreJan 12, 2024
Less than a quarter of patients with HCV receive direct-acting antiviral therapy within 6 months of diagnosis.
Read MoreJan 3, 2024
Individual, interpersonal, and structural factors influence the willingness to use PrEP among...
Read MoreJan 3, 2024
Adherence to daily PrEP is high among patients with commercial insurance, but most patients...
Read MoreJan 3, 2024
Disparities exist in rates of PrEP reversal and abandonment, according to findings published in...
Read MoreJan 3, 2024
Combining frailty measures may the improve detection of HIV-associated neurocognitive disorders (HAND), according to findings published in AIDS. David Moore, PhD, and colleagues assessed the best measure for predicting HAND in...
Read MoreSep 12, 2023
Despite progress, alarming HIV rates persist in the US. Ending the HIV Epidemic seeks to reduce annual new HIV infections to fewer than 3000 by 2030.
Read MoreSep 8, 2023
Alternative delivery models for PrEP, including pharmacists as prescribers and mail-in testing, could improve access to HIV prevention for at-risk individuals.
Read MoreAug 1, 2023
Despite HCV cure, individuals with HIV and prior HCV infection remained at higher risk for...
Read MoreJun 28, 2023
The phrase “starting at age 9” in recommendations about HPV vaccination provided clinicians with a...
Read MoreJun 22, 2023
Socioeconomic factors, such as housing, and personal identity, such as sexual orientation, jointly...
Read MoreJun 7, 2023
Increasing immunization assessments and influenza vaccination at community-based adult services...
Read More